Thousands of breast cancer patients in England are to benefit from two new drugs available on the NHS following a U-turn by the health watchdog.
About 3,500 women a year will benefit from life-extending drugs Alpelisib and Trodelvy, which have now been given the green light despite being rejected earlier this year by the National Institute for Health and Care Excellence (Nice).